MX2023013979A - Anticuerpos. - Google Patents
Anticuerpos.Info
- Publication number
- MX2023013979A MX2023013979A MX2023013979A MX2023013979A MX2023013979A MX 2023013979 A MX2023013979 A MX 2023013979A MX 2023013979 A MX2023013979 A MX 2023013979A MX 2023013979 A MX2023013979 A MX 2023013979A MX 2023013979 A MX2023013979 A MX 2023013979A
- Authority
- MX
- Mexico
- Prior art keywords
- diseases
- cd1a
- binding
- disorders
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2107517.1A GB202107517D0 (en) | 2021-05-26 | 2021-05-26 | Antibodies |
| GBGB2116709.3A GB202116709D0 (en) | 2021-11-19 | 2021-11-19 | Antibodies |
| PCT/GB2022/051285 WO2022248839A1 (en) | 2021-05-26 | 2022-05-20 | Antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013979A true MX2023013979A (es) | 2023-12-12 |
Family
ID=81927992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013979A MX2023013979A (es) | 2021-05-26 | 2022-05-20 | Anticuerpos. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240383986A1 (https=) |
| EP (1) | EP4347045A1 (https=) |
| JP (1) | JP2024522095A (https=) |
| KR (1) | KR20240013781A (https=) |
| AU (1) | AU2022282828A1 (https=) |
| CA (1) | CA3220308A1 (https=) |
| IL (1) | IL308782A (https=) |
| MX (1) | MX2023013979A (https=) |
| WO (1) | WO2022248839A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025043244A1 (en) * | 2023-08-24 | 2025-02-27 | Arizona Board Of Regents On Behalf Of Arizona State University | Tandem antigen capture assays for measuring qsox1 isoforms |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005063819A2 (en) * | 2003-12-23 | 2005-07-14 | Crucell Holland B.V. | Human binding molecule against cd1a |
| EP3046629A4 (en) | 2013-09-20 | 2017-07-12 | Children's Medical Center Corporation | Treatment of inflammatory skin disease |
| EP3696191A1 (en) * | 2019-02-14 | 2020-08-19 | Fundación Instituto de Investigación contra la Leucemia Josep Carreras (IJC) | Car t-cells for the treatment of cd1a-positive cancer |
-
2022
- 2022-05-20 EP EP22727398.4A patent/EP4347045A1/en active Pending
- 2022-05-20 WO PCT/GB2022/051285 patent/WO2022248839A1/en not_active Ceased
- 2022-05-20 JP JP2023572771A patent/JP2024522095A/ja active Pending
- 2022-05-20 MX MX2023013979A patent/MX2023013979A/es unknown
- 2022-05-20 CA CA3220308A patent/CA3220308A1/en active Pending
- 2022-05-20 IL IL308782A patent/IL308782A/en unknown
- 2022-05-20 US US18/563,440 patent/US20240383986A1/en active Pending
- 2022-05-20 KR KR1020237044497A patent/KR20240013781A/ko active Pending
- 2022-05-20 AU AU2022282828A patent/AU2022282828A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240383986A1 (en) | 2024-11-21 |
| AU2022282828A9 (en) | 2023-12-21 |
| CA3220308A1 (en) | 2022-12-01 |
| IL308782A (en) | 2024-01-01 |
| WO2022248839A1 (en) | 2022-12-01 |
| JP2024522095A (ja) | 2024-06-11 |
| KR20240013781A (ko) | 2024-01-30 |
| AU2022282828A1 (en) | 2023-12-14 |
| EP4347045A1 (en) | 2024-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022015416A2 (pt) | Anticorpos anti-ror1 e composições | |
| CO2021009693A2 (es) | Proteínas de unión a antígeno del receptor gamma anti-il2 | |
| CO2022009696A2 (es) | Anticuerpo anti-lilrb1 y usos del mismo | |
| MX2022010229A (es) | Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8). | |
| CO2026004333A2 (es) | Inhibidores de ras-pi3k para el tratamiento del cáncer y enfermedades inmunológicas | |
| CO2017007123A2 (es) | Anticuerpos biespecíficos contra calicreína y factor xii del plasma | |
| CO2021008218A2 (es) | Anticuerpos humanizados contra la región de la cadena beta de la 9na familia trbv9 del tcr humano, y sus métodos de uso | |
| ECSP23025680A (es) | Moléculas de unión a b7-h4 terapéuticas | |
| MX2023013979A (es) | Anticuerpos. | |
| CO2022019161A2 (es) | Tubulisinas y conjugados de proteína-tubulisina | |
| PE20211792A1 (es) | Anticuerpos monoclonales que se unen especificamene a la region beta de la familia trbv-9 del receptor de celulas t humano, y los metodos para su uso | |
| CO2022003661A2 (es) | Anticuerpos contra el factor de las células madre y métodos de uso de ellos | |
| BR112022026533A2 (pt) | Anticorpo anti-fxi/fxia, fragmento de ligação do mesmo, e antígenos e uso farmacêutico do mesmo | |
| CO2025008531A2 (es) | Inhibidores de malt1 | |
| BR112023020622A2 (pt) | Anticorpo anti-masp2, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo | |
| CL2025000292A1 (es) | Anticuerpos tmem219 y usos terapéuticos de los mismos | |
| CO2024007361A2 (es) | Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares | |
| CL2024003486A1 (es) | Anticuerpo anti-b7h3 y usos del mismo | |
| NI201900016A (es) | Anticuerpo o un fragmento de unión a antígeno de la cualquier capaz de vincular a un receptor humano de interleukin-6 | |
| CO2022009246A2 (es) | Anticuerpo anti-c5 para el tratamiento del trastorno del espectro de la neuromielitis óptica | |
| MX2024013649A (es) | Tratamiento de enfermedades y trastornos con compuestos que modifican la cinasa 4 asociada al receptor de interleucina 1 (irak4) | |
| CL2025002201A1 (es) | Métodos de tratamiento de trastornos neurológicos con anticuerpos anti-abeta | |
| MX2025006143A (es) | Anticuerpos anti cumulo de diferenciacion 1a (cd1a) | |
| CO2025002111A2 (es) | Formulaciones de anticuerpos contra tl1a | |
| CO2022011944A2 (es) | Moléculas de unión a antígeno contra alppl2 y/o alpp y usos de las mismas |